A phase I trial of oral ETX 1153c in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2013
At a glance
- Drugs ETX 1153 (Primary)
- Indications Clostridium-difficile-infections
- Focus Adverse reactions
- 09 Dec 2013 Status changed from planning to discontinued (e-Therapeutics is no longer planning to advance ETC 1153 into clinical development for C. difficile)
- 22 Oct 2012 Planned initiation date changed to 1 Jun 2013, according to an e-Therapeutics media release.
- 27 Jul 2011 New trial record